Neurocrine Biosciences
neurocrine.comTotal trials
86
Active
19
Phase 3
22
Total enrollment
10,195
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 6 of 6 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Valbenazine | — | — | — | 15 | |||
| NBI-1065845 | — | — | — | — | 6 | ||
| NBI-1117568 | — | — | — | — | 6 | ||
| Crinecerfont | — | — | — | — | 5 | ||
| NBI-1065890 | — | — | — | — | — | 1 | |
| NBI-1117570 | — | — | — | — | — | 1 |
Next readouts
- 2023-03-10
- 2023-07-19
- 2026-03
- 2026-04
- 2027-01
- 2027-02
- 2027-07
- 2027-07
- 2027-07
- 2027-08
Top conditions
- Schizophrenia14
- Tardive Dyskinesia11
- Major Depressive Disorder10
- Tourette Syndrome8
- Healthy Volunteers7
- Congenital Adrenal Hyperplasia5
- Parkinson's Disease4
- Chorea, Huntington3
Frequently asked questions about Neurocrine Biosciences
- How many clinical trials does Neurocrine Biosciences have on ClinicalTrials.gov?
- Neurocrine Biosciences is listed as the lead sponsor on 86 clinical trials in ClinicalTrials.gov, 19 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Neurocrine Biosciences's trials are in Phase 3?
- 22 of Neurocrine Biosciences's trials are in Phase 3, spread across 6 active drug programs.
- What therapeutic areas does Neurocrine Biosciences focus on?
- Neurocrine Biosciences's most-studied conditions on ClinicalTrials.gov are Schizophrenia, Tardive Dyskinesia, Major Depressive Disorder, Tourette Syndrome, Healthy Volunteers.
- When are Neurocrine Biosciences's next clinical trial readouts?
- Neurocrine Biosciences has 10 upcoming primary-completion readouts tracked here; the soonest is “Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)”, expected around 2023-03-10.